U.S. Pharmacogenomics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)

U.S. Pharmacogenomics Market Dynamics

Advancements in Genomic Technologies Is a Key Trend

• Medical research in pharmacogenomics utilizes DNA sequencing, microarrays, and mass spectrometry.
• Medical practitioners create complete understandings of drug-body interactions through genetic analysis, which they integrate with proteomic and metabolomic data examination.
• The multidimensional evaluation of complete proteins enables healthcare personnel to develop individualized care practices.
• The advancements of genomic technology result in the parallel progress of analytical tools.
• Biological information processing tools simplify macro-scale genomic evaluation by linking with machine learning technology.
• Pharmacogenomic testing enables medical practitioners to determine clinically important drug responses, which is critical for creating individualized therapies.
• In April 2024, the U.S. Food and Drug Administration (FDA) declared its final regulatory for medical device oversight of all laboratory-developed tests (LDTs) which includes pharmacogenomics (PGx) tests.
• The new regulatory change will affect both the creation and marketing phases of PGx tests.

Increasing Prevalence of Chronic Diseases Are the Growth Driver

• Healthcare needs continue to grow in the U.S. due to the increase in the prevalence of cancer, cardiovascular conditions, neurological disorders, and other kinds of chronic diseases.
• As per the Centers for Disease Control and Prevention, a person suffers a heart attack in the country every 40 seconds, which equals 805,000 such incidents a year.
• Moreover, 58 in 100,000 people have multiple sclerosis, which means over 123,000 people in the country have it.
• Disease management can be optimized with pharmacogenomics because it enables medical staff to use patient genetic information to select the most-beneficial treatments.
• Patients with long-term illness typically require multiple drugs, which raises the possibilities of drug–drug interactions possibilities and the side-effects of individual medicine.
• Pharmacogenomics reduces drug risk through the gene-based identification of genetic elements that lead to negative drug reactions.
• Genetic testing enables providers to identify drugs that will produce dangerous side-effects in individuals with specific genetic profiles, thereby enhancing their safety.
• In March 2024, AstraZeneca plc announced a USD 2 billion in-cash acquisition of Fusion Pharmaceuticals Inc.
• The acquisition aimed to boost AstraZeneca's ability to produce cancer treatment radiopharmaceuticals based on alpha-particle therapy, in order to achieve precision medicine advancements.

High Costs of Genetic Testing and Technology Are Major Challenge

• Genetic testing prices have decreased significantly over the years, but the total expense for genetic markers in complete pharmacogenomic tests remains substantial.
• The availability of healthcare services reduces for patients who belong to low-income and underinsured backgrounds.
• The utilization of pharmacogenomic testing faces delayed insurance coverage because both insurers and therapists doubt its clinical value and efficiency.
• The absence of insurance payment coverage for a wide range of medical treatments creates financial hurdles for healthcare providers and patients, especially those with severe and complicated conditions.

U.S. Pharmacogenomics Market Segmentation Analysis

Service Analysis

The genotyping category held the largest market share, of 45%, in 2024 since it enables oncologists, neurologists, and cardiologists to analyze genetic drug metabolism, which facilitates better clinical decision-making. Genotyping services continue to witness a high demand because they enable better therapeutic results and help diminish drug side effects.

The pharmacogenetic testing category will grow at the highest CAGR, of 11.5%, during the forecast period. This is because medical practitioners and patients are showing increasing interest in personalized healthcare and genetic testing for prenatal disease detection.

The services analyzed here are:

• Genotyping (Largest Category)
• SNP Identification
• Pharmacogenetic Testing (Fastest-Growing Category)
• Others

Application Analysis

The oncology category held the largest market share, of 55%, in 2024 because of the increasing usage of genetic information to make treatments specific to each unique cancer patient. The examination of patients’ genetic characteristics and tumor profiles through pharmacogenomics lets doctors design specific therapies, which raises treatment effectiveness while decreasing treatment-associated complications. Studies had predicted over 2.1 million new cancer cases and over 611,000 deaths in the country in 2024.

In February 2025, Merck KGaA acquired Springworks Therapeutics for around USD 4 billion to develop its oncology portfolio and establish a stronger U.S. presence.

The neurology category will grow at the highest CAGR, of 12%, during the forecast period because the current neurological research and clinical practice revolve around the precision medicine. Neurological genetic testing is increasingly being used in clinical practice and research to determine appropriate medications for neurological disorders.

The applications analyzed here are:

• Oncology (Largest Category)
• Infectious Diseases
• Neurology (Fastest-Growing Category)
• Cardiovascular Diseases
• Others

End User Analysis

The research organizations category held the largest market share, of 40%, in 2024 because pharmacogenomic-based treatment discovery and development takes place primarily at research organizations. State-backed and independent research institutions perform critical research on drug efficacy and metabolism, offering results that pharmaceutical companies utilize for developing targeted therapies.

The diagnostic centers category will grow at the highest CAGR, of 12.5%, during the forecast period. This is because diagnostic centers provide pharmacogenomic tests to evaluate drug reaction patterns based on patient DNA, to enable individual medicine prescriptions. Personalized medicine requirements are impelling healthcare professionals to rapidly integrate pharmacogenomics testing into their clinical practice. Moreover, the development of genomic testing tools and their integration with sequencing technologies allow diagnostic centers to increase the scale of pharmacogenomic testing.

The end users analyzed here are:

• Research Organizations (Largest Category)
• Pharmaceutical Companies
• Diagnostic Centers (Fastest-Growing Category)
• Others

U.S. Pharmacogenomics Market Regional Outlook

The Western region held the largest market share, of 45%, in 2024, because it stands as a major technological and scientific innovation hub, led by California. Genomic research and precision medicine are prominent subjects and areas of focus among researchers in this region. The established medical sector here also enabled genetic testing to be available to people sooner than in other regions.

The Southern region will grow at the highest CAGR, of 12%, because of the presence of several major hospitals, research institutions, and other kinds of medical centers. Moreover, being the poorest region in the country, the South has a vast unmet need for effective yet affordable treatments. This, combined, with the huge patient base, offers lucrative opportunities for companies conducting research on pharmacogenomics, as well as those using these concepts for diagnosis and treatment.

The regions analyzed in this report are:

• Northeast
• Midwest
• West (Largest Category)
• South (Fastest-Growing Category)

U.S. Pharmacogenomics Market Share

The market is fragmented in nature because the field continues to develop, which gives numerous businesses ample space to expand their operations, along with opportunities to achieve success. Different service providers choose distinct genetic study methods from PCR to phenotyping and NGS, among others. Various therapeutic fields needing pharmacogenomic assessments fragment the market because most companies choose to focus on select pharmaceuticals and disease types. Smaller businesses are actively entering the market with different concepts for genetic testing, customized drug treatments, and software programs.